Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.9165
- Book/Share -0.0779
- PB -2242.0157
- Debt/Equity -385.1421
- CurrentRatio 0.7358
- ROIC 0.1416
- MktCap 409028897900.0
- FreeCF/Share 10.2929
- PFCF 22.4261
- PE 108.8588
- Debt/Assets 0.5138
- DivYield 0.0279
- ROE 1.4231
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral
Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to AbbVie's Massachusetts sites and workforce NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass.
Read More
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral
– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Read More
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Published: September 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.
Read More
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Read More
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Published: September 29, 2025 by: PRNewsWire
Sentiment: Neutral
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by 2027 Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing NORTH CHICAGO, Ill. , Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
AbbVie to launch ovarian cancer drug in UK at the same list price as US
Published: September 29, 2025 by: Reuters
Sentiment: Positive
AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.
Read More
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
Read More
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape.
Read More
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.
Read More
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
Read More
AbbVie shares rise with extension of RINVOQ patent protection to 2037
Published: September 11, 2025 by: Proactive Investors
Sentiment: Positive
Abbvie Inc (NYSE:ABBV) shares moved higher after the pharma company announced it has secured extended patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib). It said in a regulatory filing that it has reached settlements with all generic manufacturers that had filed applications to produce generic versions of RINVOQ, effectively extending US patent protection until April 2037, assuming pediatric exclusivity is granted.
Read More
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
Published: September 11, 2025 by: Reuters
Sentiment: Positive
AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts.
Read More
AbbVie in Settlement With Generic Drugmakers on Rinvoq
Published: September 11, 2025 by: WSJ
Sentiment: Positive
The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
AbbVie: What's Happening With ABBV Stock?
Published: September 11, 2025 by: Forbes
Sentiment: Positive
AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq, until 2037.
Read More
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Read More
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
Published: September 08, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss the latest Calls of the Day.
Read More
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Read More
AbbVie Declares Quarterly Dividend
Published: September 05, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Read More
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
Read More
Investing in the Age of Longevity: Silver Economy Stocks in Focus
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Read More
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Read More
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Best Dividend Aristocrats For September 2025
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.
Read More
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
Read More
AbbVie: Plenty Of Positives
Published: August 26, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in using Rinvoq to treat alopecia and even the expansion of its neuroscience portfolio support ABBV. However, the recent acquisition of a depression treatment candidate can impact the earnings outlook at a time when its market multiples already look stretched.
Read More
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter's lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed for treating major depressive disorder(MDD).
Read More
AbbVie Is A Top Biotech Pick
Published: August 25, 2025 by: Seeking Alpha
Sentiment: Positive
Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential and U.S. manufacturing plans are likely to help mitigate tariff headwinds successfully. EPS guidance for the full year was raised and consensus estimates also show that the outlook for AbbVie is a strong one.
Read More
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion
Published: August 25, 2025 by: Reuters
Sentiment: Positive
AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael CPA
- Employees 55000